The European approval is based on results from the Phase III KEYNOTE-B96 trial, which also supported the regimen's approval in the US.
Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior sys ...
Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and spotlighting new targets like HER2 and Claudin 18.2. Ronan J. Kelly, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results